Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
Adjuvants, Immunologic
/ administration & dosage
Administration, Intravesical
Adult
Aged
Aged, 80 and over
BCG Vaccine
/ administration & dosage
Basophils
/ pathology
Cystectomy
/ methods
Disease Progression
Female
Follow-Up Studies
Humans
Leukocyte Count
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnosis
Neoplasm Staging
/ methods
Neutrophils
/ pathology
Retrospective Studies
Time Factors
Urinary Bladder Neoplasms
/ pathology
BCG
Basophils
Bladder cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
09
01
2019
accepted:
01
04
2019
pubmed:
18
4
2019
medline:
12
11
2020
entrez:
18
4
2019
Statut:
ppublish
Résumé
Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09-1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12-1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01-1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1-1.68); p = 0.005]. The limitations of a retrospective study are applicable. Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG.
METHODS
METHODS
We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model.
RESULTS
RESULTS
A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09-1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12-1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01-1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1-1.68); p = 0.005]. The limitations of a retrospective study are applicable.
CONCLUSION
CONCLUSIONS
Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.
Identifiants
pubmed: 30993426
doi: 10.1007/s00345-019-02754-2
pii: 10.1007/s00345-019-02754-2
doi:
Substances chimiques
Adjuvants, Immunologic
0
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-150Références
BJU Int. 2010 Aug;106(4):493-9
pubmed: 20067452
Int J Cancer. 2003 Nov 10;107(3):434-40
pubmed: 14506744
Lancet. 2007 Oct 20;370(9596):1422-31
pubmed: 17950857
Chem Immunol Allergy. 2006;90:141-156
pubmed: 16210908
Clin Exp Immunol. 2002 Oct;130(1):93-100
pubmed: 12296858
Annu Rev Immunol. 2011;29:45-69
pubmed: 21166539
Nat Immunol. 2010 Jul;11(7):608-17
pubmed: 20495560
Clin Exp Immunol. 2002 Jan;127(1):20-6
pubmed: 11882028
Crit Rev Oncol Hematol. 2015 Dec;96(3):534-41
pubmed: 26520458
Urol Oncol. 2018 Sep;36(9):389-399
pubmed: 29884342
Nat Rev Urol. 2018 Oct;15(10):615-625
pubmed: 29991725
Cytokine. 2003 Jan 7;21(1):17-26
pubmed: 12668155
Am J Respir Crit Care Med. 1999 Dec;160(6):1816-23
pubmed: 10588591
World J Urol. 2019 Jan;37(1):3-13
pubmed: 30105454
Stat Med. 2009 Aug 30;28(19):2473-89
pubmed: 19472308
F1000Res. 2017 Aug 15;6:1464
pubmed: 28868143
Eur Urol. 2014 Jul;66(1):59-73
pubmed: 24451595
Clin Microbiol Rev. 1996 Oct;9(4):532-62
pubmed: 8894351
Cancer Res. 2016 Apr 1;76(7):1792-803
pubmed: 26873846
Eur Urol. 2016 Jan;69(1):60-9
pubmed: 26210894
Front Immunol. 2015 Aug 03;6:393
pubmed: 26284076
Clin Genitourin Cancer. 2018 Dec;16(6):445-452
pubmed: 30077463
J Urol. 2013 Aug;190(2):480-6
pubmed: 23376707
Cancer Immunol Immunother. 1995 Feb;40(2):103-8
pubmed: 7882379
J Exp Med. 2011 Mar 14;208(3):469-78
pubmed: 21339327
J Urol. 2002 Jan;167(1):364-7
pubmed: 11743357